ArticleThe Journal of biological chemistry2020
Global reprogramming of virulence and antibiotic resistance in
Article in The Journal of biological chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 30 citations in OpenAlex.
- Genomic and Phenotypic Insights into Carbapenem-ResistantMicroorganisms · 2026Article
- Experimental evolution reveals adaptive pathways to reduced antibiotic susceptibility inMicrobiology (Reading, England) · 2026Article
- Intermittent antibiotic exposure of Escherichia coli biofilms drives resistance in catheter-associated infection models.NPJ biofilms and microbiomes · 2026Article
- Genomic Analysis ofInternational journal of microbiology · 2026Article
- Pathogenicity and virulence ofVirulence · 2025Review
- Selective silencing of antibiotic-tethered ribosomes as a resistance mechanism against aminoglycosides.Nature communications · 2025Article
- Article
- Regulation, structure, and activity of theAntimicrobial agents and chemotherapy · 2025Review
- Anaerobiosis and Mutations Can Reduce Susceptibility ofPathogens (Basel, Switzerland) · 2025Article
- Macrolide resistance through uL4 and uL22 ribosomal mutations in Pseudomonas aeruginosa.Nature communications · 2024Article
- An Amino Acid Substitution in Elongation Factor EF-G1A Alters the Antibiotic Susceptibility of Pseudomonas aeruginosa LasR-Null Mutants.Journal of bacteriology · 2023Article
- Gene-Gene Interactions Reduce Aminoglycoside Susceptibility ofAntibiotics (Basel, Switzerland) · 2023Article
- Adaptation ofMicrobiology (Reading, England) · 2023Article
- Aminoglycoside-Modifying Enzymes Are Sufficient to MakeAntibiotics (Basel, Switzerland) · 2022Article
- Convergent phenotypic evolution towards fosfomycin collateral sensitivity of Pseudomonas aeruginosa antibiotic-resistant mutants.Microbial biotechnology · 2022Article
- Antibiotic Resistance in Pseudomonas.Advances in experimental medicine and biology · 2022Article
- What Makes Pseudomonas aeruginosa a Pathogen?Advances in experimental medicine and biology · 2022Article
- The Quorum-Sensing Inhibitor Furanone C-30 Rapidly Loses Its Tobramycin-Potentiating Activity against Pseudomonas aeruginosa Biofilms during Experimental Evolution.Antimicrobial agents and chemotherapy · 2021Article
- Genome-wide association study of signature genetic alterations among pseudomonas aeruginosa cystic fibrosis isolates.PLoS pathogens · 2021Article
- Clinical Strains ofJournal of inflammation research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 2 countries.
Funding
Abstract
Clinical isolates of the opportunistic pathogen
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.